来自中山大学肿瘤防治中心肿瘤国家重点实验室的研究人员发现了鼻咽癌血清诊断的一种新标记，这对于鼻咽癌的诊断和治疗具有积极意义。这一研究成果公布在Journal of General Virology杂志上。
长期以来，Epstein–Barr 病毒（简称EB病毒）一直被认为是人类某些严重疾病以及肿瘤的致病因子，它与许多疾病的发生都有着密切的关系，威胁着人类的健康，因而一直倍受关注。
之前的研究显示，IgA 和（或）IgG对几种不同的EB病毒的不同反应有利于鼻咽癌NPC的诊断，但是不同抗体对gp78的作用至今并未进行相关研究。
在这篇文章中，研究人员利用Luminex的multi-analyte profiling (xMAP)技术，分析抗体对gp78合成多肽的反应（样品包括95位鼻咽癌病患样品和91个阴性对照），结果研究人员发现NPC针对的IgA-gp78特异性是71％，而IgG-gp78则是73％。
之后研究人员还通过一系列组合方式进行研究，最后确定针对EB病毒的gp78的抗体是一种对于鼻咽癌xMAP技术检测血清诊断的新标记，这对于鼻咽癌的诊断和治疗具有积极意义。（生物谷Bioon.com）
生物谷推荐原始出处：
J Gen Virol 89 (2008), 1152-1158; DOI 10.1099/vir.0.83686-0
Antibodies against Epstein–Barr virus gp78 antigen: a novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology
Ai-Di Gu1, Yan-Bo Xie1, Hao-Yuan Mo1,2, Wei-Hua Jia1, Miao-Yan Li3, Ming Li3, Li-Zhen Chen1, Qi-Sheng Feng1, Quentin Liu1, Chao-Nan Qian1,2 and Yi-Xin Zeng1
1 State Key Laboratory of Oncology in Southern China, Department of Experimental Research, Cancer Center, Sun Yat-Sen University, Guangzhou, PR China
2 State Key Laboratory of Oncology in Southern China; Department Nasopharyngeal Carcinoma, Cancer Center, Sun Yat-Sen University, Guangzhou, PR China
3 Da'an Gene Diagnostic Center, Sun Yat-Sen University, Guangzhou, PR China
Immunoglobulin (Ig) A and/or IgG reactivities to several Epstein–Barr virus (EBV) antigens have been used to facilitate diagnosis of nasopharyngeal carcinoma (NPC). However, antibodies against gp78, an EBV membrane glycoprotein, have not been examined to this day. In this study, we utilized Luminex multi-analyte profiling (xMAP) technology to analyse antibody responses to a synthetic peptide of gp78 in sera samples from 95 NPC patients and 91 healthy controls. Our results showed the sensitivity and specificity of IgA-gp78 for NPC diagnosis were 79 and 71 %, respectively, while those of IgG-gp78 were 74 and 73 %, respectively. The IgA and IgG responses to different EBV antigens were not identical within an individual and IgA-gp78 and IgG-gp78 could be complementary to antibodies against viral capsid antigen (VCA), the diffused early antigen (EA-D) and the nuclear antigen EBNA1 for NPC diagnosis. When the six EBV parameters for NPC prediction, i.e. IgA-gp78, IgG-gp78, IgA-VCA, IgA-EBNA1, IgA-EA-D and IgG-EA-D, are combined, the combined predictors were able to reach overall sensitivity and specificity of 91 and 95 %, respectively. Thus, simultaneous detection of these EBV serological markers could improve the predictive values of NPC using xMAP technology.
